IMPACT
DEAD

Serial Number

88686161

Owner

PACT Pharma, Inc.

Attorney

Cara R. Baer

First Use Date

May 1, 2017

Filing Date

Nov 9, 2019

Add to watchlist:

No watchlists yet
View on USPTO

IMPACT Trademark

Serial Number: 88686161 • Registration: 6183342

IMPACT is a trademark filed by PACT Pharma, Inc. on November 9, 2019. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

PACT Pharma, Inc. (22 trademarks)

2 Corporate Drive
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

November 9, 2019

Registration Date

October 27, 2020

First Use Anywhere

May 1, 2017

First Use in Commerce

May 1, 2017

Published for Opposition

August 11, 2020

Cancellation Date

November 8, 2023

Goods & Services

Scientific analysis services, namely, neoepitope selection; neoepitope research, development and production of pharmaceuticals comprising personalized adoptive cell therapies; scientific analysis of neoepitopes; research, development and production of pharmaceuticals comprising the selection of and genetic encoding of neoepitopes; research, development and production of pharmaceuticals comprising adoptive cell therapies design of personalized adoptive cell therapies; medical analysis services, namely, detection of truncal cancer mutations in patient tumor cells; developing personal scientific treatment strategies for patients with diagnosed cancer; pharmaceutical product development and evaluation services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials involving neoepitopes; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; scientific collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; Conducting early evaluations in the field of new pharmaceuticals; Providing scientific research advice regarding selection of a neoepitope for the design of a cell therapy and/or immunotherapy product

Filing History

NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED
Nov 9, 2023 NCS7
CANCELLED SECTION 7-TOTAL
Nov 8, 2023 C7..
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 7, 2023 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 7, 2023 APRE
REQUEST FOR SECT 7 TOTAL SURRENDER FILED
Jun 16, 2023 C7RF
TEAS SECTION 7 SURRENDER RECEIVED
Jun 16, 2023 ES7S
REGISTERED-PRINCIPAL REGISTER
Oct 27, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 11, 2020 NPUB
PUBLISHED FOR OPPOSITION
Aug 11, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 22, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 9, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 7, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 7, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Feb 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Feb 20, 2020 CNRT
ASSIGNED TO EXAMINER
Feb 13, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 16, 2019 NWOS
NEW APPLICATION ENTERED
Nov 13, 2019 NWAP